Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?

To: StockDung who wrote (308)	6/8/2000 4:06:00 PM
From: Jeffrey S. Mitchell	Respond to of 12465

Re: 6/2/00 - Hemispherx: Price Waterhouse Submits Findings on Short Seller Damages Hemispherx: Price Waterhouse Submits Findings on Short Seller Damages PHILADELPHIA, June 2 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) said that independent accounting firm Price Waterhouse is submitting its report to federal court today regarding its findings of the magnitude of damages owed to Hemispherx by short sellers against whom Hemispherx has brought civil suits. Hemispherx said that Price Waterhouse conducted the study under commission from Hemispherx and is submitting its findings to the Eastern District Federal Court of Pennsylvania in Philadelphia. The report is based on Price Waterhouse's determination of the extent to which the short sellers' allegations, which were published in numerous press releases and documents that the short sellers called research reports, were materially false and misleading. Price Waterhouse also examined detailed data comparing the short sellers' trading in Hemispherx's stock to the dates that they issued materially false and misleading publications. The damages are expected to reach into the tens of millions of dollars. Hemispherx's lead drug, Ampligen, is the only new drug product being developed world-wide at the Phase III clinical level for severely debilitating forms of CFS, a disease estimated to afflict more than 1 million people worldwide. For North American clinical programs, the Ampligen(R) product is presently manufactured utilizing the Schering-Plough facilities in Puerto Rico. Polyadenur and Ampligen raw materials have both been produced at Ribotech, in Capetown, South Africa as a joint venture company of Hemispherx and Bioclones. Finished drug product is also produced at F.H. Faulding Limited, the largest Australian pharma company, to supplement ongoing global clinical programs. Contact(s): William A. Carter, M.D., CEO & Chairman, HEMISPHERx BIOPHARMA, INC., 215-988-0080 Dianne Will, Investor Relations, 214-954-9300, Fax: 214-954-9333 Mark Kollar, Institutional Investors, 212-232-2222, Fax: 212-232-3232 HEB's Web Site: hemispherx.com Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of HEMISPHERx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward looking statements. -------------------------------------------------------------------------------- SOURCE: Hemispherx Biopharma, Inc. CONTACT: William A. Carter, M.D., CEO & Chairman, HEMISPHERx BIOPHARMA, INC., 215-988-0080, Dianne Will, Investor Relations, 214-954-9300, fax 214-954-9333, or Mark Kollar, Institutional Investors, 212-232-2222, fax 212-232-3232 siliconinvestor.com

To: StockDung who wrote (308)	6/8/2000 4:11:00 PM
From: Jeffrey S. Mitchell	Respond to of 12465

Hemispherx is a Stratton Oakmont stock fraud controlled by William A. Carter who has been charged with medical and scientific fraud and is being investigated for stock fraud. ROFLMAO! Sounds like something you'd write (gg). Interesting to see that Asensio won in court (and rightfully so, IMO... but on jurisdiction, not merits), yet less that a week prior HEB issued a PR (see previous post) that certainly indicated a different result was expected. - Jeff

To: StockDung who wrote (308)	6/8/2000 4:17:00 PM
From: Jeffrey S. Mitchell	Read Replies (3) \| Respond to of 12465

Re: 6/8/00 - Hemispherx: Federal Court Rules on Short Sellers' Jurisdiction Motion Thursday June 8, 9:45 am Eastern Time Company Press Release SOURCE: Hemispherx Biopharma, Inc. Hemispherx: Federal Court Rules on Short Sellers' Jurisdiction Motion PHILADELPHIA, June 8 /PRNewswire/ -- Hemispherx Biopharma, Inc. (Amex: HEB; HEBws) today said that a federal court ruled that it does not have jurisdiction in the defamation case that the Company brought against certain short sellers. The federal court did not make any ruling concerning merits of the case and the Company has the option to pursue its charges in state courts. In the motion that the United States District Court allowed yesterday, the short sellers claimed that the federal court has no jurisdiction to adjudicate the truth or falsity of statements that the short sellers made about the Company. The short sellers also argued that the federal court is without jurisdiction to adjudicate the claims that the short sellers themselves asserted against the Company in the case. ``The only effect of the granting of the short sellers motion is to delay adjudication of the merits of the parties' various claims,'' explained Michael Arthur Walsh, one of the Company's lawyers, ``But this settles nothing.'' ``Apparently, the short sellers are not eager to try the truth of their statements about the Company in an open, public forum where their accusations must be supported by factual evidence,'' said Dr. William A. Carter, Chairman and Chief Executive Officer of Hemispherx. ``I would have thought that anyone who actually believed the various things that the short sellers published about the Company would have been anxious to allow the case to proceed as quickly as possible. Their motion to push the case to a different jurisdiction is clearly a delaying tactic. It speaks clearly about the merit of their case.'' Hemispherx said that its pursuit of the dismissed case had not been deterred by the actions of the short sellers which included allegedly dissolving their hedge fund Asensio Capital Management, destroying massive amounts of evidence including essentially all trading records required to be kept by NASD, and returning the money under management to investors. Hemispherx is reporting to the Justice Department certain information regarding the nature of the funding of the dissolved Asensio Capital Management and the web of other entities that the Company claims were involved in illegal short selling. Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. SOURCE: Hemispherx Biopharma, Inc. biz.yahoo.com